Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × pidilizumab × Clear all
NCT02077959 2023-01-27

Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Ohio State University Comprehensive Cancer Center

Phase 1 Terminated
20 enrolled
Plasma cell

Multiple Myeloma

NCT01386502 2017-07-02

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡